Table 1.
Patient characteristics.
| Number of patients (44) | % | |
|---|---|---|
| Gender | ||
| Female | 15 | 34 |
| Male | 29 | 66 |
| Median Age | 56 | |
| Age Range | 28–87 | |
| Familial Syndrome | 4 | 9 |
| SDHB mutation | 3 | 7 |
| MEN1 | 1 | 2 |
| Site of Primary Carcinoid | 17 | 39 |
| - Lung | 6 | |
| - Small Bowel | 6 | |
| - Appendix | 1 | |
| - Large Bowel | 3 | |
| - Unknown Primary | 1 | |
| Pancreatic NET | 9 | 20 |
| - Gastrinoma | 1 | |
| - Glucagonoma | 3 | |
| - Insulinoma | 1 | |
| - Non-functioning | 4 | 9 |
| Catecholamine secreting | 7 | 16 |
| - Phaeochromocytoma | 1 | |
| - Paraganglioma | 6 | |
| Thyroid | 4 | 9 |
| - Hürthle Cell | 1 | |
| - Medullary Carcinoma | 3 | |
| Head and Neck Adenocarcinoma | 3 | 7 |
| NET of Unknown Primary | 4 | 9 |
| Metastatic disease | 44 | 100 |
| - Bone | 23 | 52 |
| - Brain | 3 | 7 |
| - Liver | 29 | 65 |
| - Lung | 14 | 32 |
| - Lymph Node | 32 | 72 |
| - Peritoneal | 5 | 11 |
| Previous Treatments | 44 | 100 |
| - Surgery | 26 | 59 |
| - PRRT | 5 | 11 |
| - RT | 10 | 22 |
| - Somatostatin Analogue | 18 | 40 |
| - Chemo | 13 | 29 |
| - Nil | 4 | 9 |
| Treatments after Lu-DO | 18 | 40 |
| - Surgery | 2 | 5 |
| - PRRT | 3 | 7 |
| - Somatostatin Analogue | 2 | 5 |
| - Chemo | 7 | 16 |
The numbers in bold represent the number of patients for each main category.